Patients with loss-of-function mutations in BRCA1 or BRCA2 can present with a more aggressive BC phenotype, including triple-negative BC (TNBC) [3, 10, 11], higher tumour grade [12], and higher oncotype risk of recurrence score [13]. The gene discussed is BRCA1; the disease is neoplasm.